Low-energy shock wave for enhancing recruitment of endothelial progenitor cells: a new modality to increase efficacy of cell therapy in chronic hind limb ischemia by Aicher, A et al.
ISSN: 1524-4539 
Copyright © 2006 American Heart Association. All rights reserved. Print ISSN: 0009-7322. Online
72514
Circulation is published by the American Heart Association. 7272 Greenville Avenue, Dallas, TX
DOI: 10.1161/CIRCULATIONAHA.106.628623 
 published online Dec 4, 2006; Circulation
M. Zeiher and Stefanie Dimmeler 
Alexandra Aicher, Christopher Heeschen, Ken-ichiro Sasaki, Carmen Urbich, Andreas
 Limb Ischemia
Cells. A New Modality to Increase Efficacy of Cell Therapy in Chronic Hind 
Low-Energy Shock Wave for Enhancing Recruitment of Endothelial Progenitor
 http://circ.ahajournals.org
located on the World Wide Web at: 
The online version of this article, along with updated information and services, is
 http://www.lww.com/reprints
Reprints: Information about reprints can be found online at 
  
 journalpermissions@lww.com
410-528-8550. E-mail: 
Fax:Kluwer Health, 351 West Camden Street, Baltimore, MD 21202-2436. Phone: 410-528-4050. 
Permissions: Permissions & Rights Desk, Lippincott Williams & Wilkins, a division of Wolters
  
 http://circ.ahajournals.org/subscriptions/
Subscriptions: Information about subscribing to Circulation is online at 
 by on June 24, 2010 circ.ahajournals.orgDownloaded from 
Low-Energy Shock Wave for Enhancing Recruitment of
Endothelial Progenitor Cells
A New Modality to Increase Efficacy of Cell Therapy in Chronic Hind
Limb Ischemia
Alexandra Aicher, MD*; Christopher Heeschen, MD*; Ken-ichiro Sasaki, MD; Carmen Urbich, PhD;
Andreas M. Zeiher, MD; Stefanie Dimmeler, PhD
Background—Stem and progenitor cell therapy is a novel approach to improve neovascularization and function of
ischemic tissue. Enhanced tissue expression of chemoattractant factors such as stromal cell–derived factor 1 and
vascular endothelial growth factor is crucial for the recruitment of circulating endothelial progenitor cells (EPCs) during
acute ischemia. In chronic ischemia, however, expression of these chemoattractants is less pronounced, which results
in insufficient EPC recruitment into the target tissue. Therefore, we investigated the effect of targeted extracorporeal
shock wave (SW) application in order to facilitate EPC recruitment into nonischemic and chronic ischemic tissue.
Methods and Results—Hind limb adductor muscles of nude rats were treated with 500, 1000, and 2000 impulses of
focused low-energy SW (flux density level: 0.05 mJ/mm2). Twenty-four hours later, mRNA expression of the
chemoattractant stromal cell– derived factor 1 was significantly increased with 1000 impulses (stromal cell–
derived factor 1/GAPDH: 0.950.09) and 2000 impulses (stromal cell– derived factor 1/GAPDH: 1.170.24; both
P0.05 versus untreated). Histologically, the number of vascular endothelial growth factor–positive endothelial
cells per myocyte was significantly increased with 2000 impulses (0.240.05 versus 0.090.02; P0.01). This
preconditioning effect resulted in significantly enhanced recruitment and homing of EPCs that were intravenously
infused 24 hours after SW treatment (P0.05). In a rat model of chronic hind limb ischemia, SW-facilitated EPC
treatment resulted in a significant increase in relative blood flow recovery as assessed by laser Doppler imaging
(P0.05).
Conclusions—Preconditioning of both nonischemic and chronic ischemic tissue with low-energy SW improves
recruitment of circulating EPCs via enhanced expression of chemoattractant factors. Thus, SW-facilitated cell
therapy may improve the efficacy of EPC treatment in patients with chronic ischemia. (Circulation. 2006;114:
&NA;-.)
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Stem or progenitor cell therapy is a novel approach toimprove functional recovery of ischemic tissue. Experi-
mental studies and, more recently, phase II and III clinical
trials documented that administration of bone marrow–de-
rived or peripheral blood–derived progenitor cells increased
neovascularization and reduced infarct size and scar forma-
tion after myocardial infarction.1–7 Mobilized as well as
infused progenitor cells are selectively recruited to ischemic
tissue, whereas their incorporation into nonischemic heart or
hind limb tissue is an extremely rare event.8 The recruitment
and incorporation of progenitor cells is augmented by growth
factors and chemokines such as vascular endothelial growth
factor (VEGF) and stromal cell-derived factor 1 (SDF-1),
which are both upregulated in ischemia tissue.9–13 Endothelial
progenitor cells (EPCs) are well endowed with receptors for
VEGF (VEGF receptor 2) and SDF-1 (CXCR4), which
allows them to sense their way through the circulation to
home to sites of acute ischemic injury. In contrast to acute
ischemia, however, nonischemic or chronic ischemic tissue is
characterized by a markedly lower expression of chemoat-
tractant factors resulting in a reduced capacity to recruit a
reasonable number of EPCs.14–17
Clinical Perspective p ●●●
High-energy extracorporeal shock wave (SW) therapy is
commonly used to fragmentize kidney stones for 20
years.18 At lower energy levels, however, SWs exert
distinct vascular effects such as augmentation of neovas-
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cularization in a pig model of myocardial infarction.19
Moreover, a first clinical study in patients with severe
coronary artery disease indicates that repetitive extracor-
poreal cardiac SW therapy may improve myocardial per-
fusion and clinical symptoms.20 These vascular effects are
most likely mediated through enhanced expression of
VEGF and nitric oxide.19,21–23 Because VEGF is a potent
chemoattractant for progenitor cells, we reasoned that
preconditioning of the target tissue with low-dose energy
SW therapy may enhance EPC recruitment.
Indeed, our data demonstrate that low-energy SW ther-
apy is capable of augmenting expression of VEGF and
SDF-1 and subsequently enhancing recruitment of system-
ically infused progenitor cells to nonischemic and, most
important, chronic ischemic tissue.
Methods
Isolation of EPCs
EPCs were isolated and cultivated as described previously.24 In
short, mononuclear cells were isolated by density-gradient centrifu-
gation from human peripheral blood with Biocoll separating solution
(density 1.077; Biochrom AG, Berlin, Germany). Immediately after
isolation, 8106 mononuclear cells/mL medium were plated on
fibronectin-coated culture dishes and maintained in endothelial basal
medium (Cambrex, Verviers, Belgium) supplemented with endo-
thelial growth medium SingleQuots (Cambrex) and 20% fetal calf
serum (Gibco, Berlin, Germany). After 3 days in culture, nonadher-
ent cells were removed by thorough washing with PBS. Adherent
EPCs were characterized by dual-staining for 1,1-dioctadecyl-
3,3,3,3-tetramethylindocarbocyanine-labeled acetylated low-
density lipoprotein and lectin and by the expression of endothelial
marker proteins KDR, VE-cadherin, eNOS, and von Willebrand
factor.25
Animals
To inject xenogenic human EPCs into rats, we used athymic
immunocompromised nude rats (Hsd:RH-Foxn1rnu; Harlan, Borchen,
Germany) at the age of 5 weeks. During SW therapy, animals were
anesthetized with medetomidine (0.1 mg/kg) and were administered
carprofen (5 mg/kg) for analgesia.
Chronic Hind Limb Ischemia Model
The in vivo neovascularization capacity of EPCs was investigated in
a rat model of unilateral hind limb ischemia. The proximal portion of
the right femoral artery, including the superficial and the deep branch
as well as the distal portion of the saphenous artery were occluded
with an electrical coagulator. The overlying skin was closed with
surgical staples. After about 3 weeks, SW preconditioning was
performed. Twenty-four hours after SW therapy, a total dose of 106
EPCs was intravenously injected. Limb perfusion was assessed after
2 weeks using laser Doppler imaging (Moore, Axminster, UK).
SW Treatment
The SW device (Dornier Biotripter, Wessling, Germany) is a
prototype based on a commercially available lithotripter that was
equipped with a newly developed low-energy SW source. The SW
source comprised an integrated ultrasound transducer for image-
guided localization of the treatment area. The focal point of the SW
source was indicated by a cross-hair on the ultrasound monitor
adjusted to the center of the adductor muscle. The penetration depth
was adjusted using an inflatable bellow under control of the
integrated ultrasound. The pressure field generated by this device is
characterized by an ellipsoidal cigar-shaped focal zone (“line focus”)
in the plane perpendicular to the direction of SW propagation. We
applied an energy flux density of 0.05 mJ/mm2 and delivered 500,
1000, and 2000 impulses. In some animals, hind limb ischemia was
employed instead of SW therapy as a positive control. If subsequent
cell therapy was performed, a total of 106 EPCs were intravenously
injected 24 hours after SW preconditioning or induction of hind limb
ischemia.
Polymerase Chain Reaction
Twenty-four hours after SW application, animals were euthanized
and adductor muscles from the treated right and untreated left hind
limb were harvested. Total RNA (RNA minikit, Qiagen, Hilden) was
isolated from snap-frozen tissue and was subjected to polymerase
chain reaction (Applied Biosystems, Foster City, Calif). To amplify
rat SDF-1, we used the following primers: rat SDF-1 sense 5-
GCCCCTGCCGATTCTTTGAG -3, antisense 5-GTCCAGGTACT-
CTTGGATCCAC-3 (SDF-1 band 164 bp); GAPDH sense 5-TCA-
CCATCTTCCAGGAGCGAGATC-3, antisense 5-GAGACCACC-
TGGTGCTCAGTGTAG-3 (GAPDH band 511 bp). Polymerase chain
reaction reagents were from Invitrogen (Karlsruhe, Germany). Polymer-
ase chain reaction products were analyzed on 3% and 1.5% agarose gels
for SDF-1 and GAPDH, respectively.
Histological Analysis
The harvested tissues were embedded in paraffin or cryopreserved
in OCT compound (TissueTek, Sakura, The Netherlands), fol-
lowed by preparation of 5-m cryosections, fixation in acetone
for 2 minutes, and blocking for 30 minutes in PBS1% BSA. To
assess the morphological integrity, paraffin-embedded tissue was
analyzed by hematoxylin & eosin staining. Moreover, immuno-
histochemistry for the membrane marker laminin was used to
examine the integrity of the cellular membrane. For quantification
of apoptotic cells, we used an in situ DNA nick-end labeling assay
kit from Roche (Mannheim, Germany) according to the manufac-
turer’s instructions.
Recruitment of infused EPCs was assessed by labeling EPCs
with red fluorescent CM-Dil prior to intravenous injection and
then by staining the cryosections for the endothelial marker
anti–von Willebrand factor–FITC (1:50; Acris, Hiddenhausen,
Germany), the membrane marker anti-laminin (1:50; Invitrogen)
followed by anti-rabbit immunoglobulin Alexa647 (1:400; In-
vitrogen) and nuclear staining with Sytox blue (1:2000;
Invitrogen).
VEGF staining was performed with anti-VEGF antibody in
frozen sections (1:50 in PBS1% BSA; R&D Systems, Minne-
apolis, Minn) overnight at 4°C. After washing twice with PBS,
the secondary step antibody anti-mouse Alexa 488 (1:200, In-
vitrogen) and the nuclear stain Sytox (1:2000, Invitrogen) were
incubated for 60 minutes at room temperature. Samples were
analyzed with an LSM 510 confocal microscope (Zeiss, Jena,
Germany).
Statistical Analysis
Results are expressed as meanSEM. Overall comparison of the
treatment groups was performed with the Kruskal-Wallis test fol-
lowed by post hoc pairwise comparison using the Mann-Whitney
test. Probability values 0.05 were considered statistically signifi-
cant. All analyses were performed with SPSS 11.5 (SPSS Inc,
Chicago, Ill).
The authors had full access to the data and take full responsi-
bility for the integrity of the data. All authors have read and agree
to the manuscript written.
Results
Effect of In Vivo SW Treatment on the Expression
of Chemoattractant Factors
First, we investigated whether SW therapy exerts a precon-
ditioning effect by inducing chemoattractant factors in the
targeted nonischemic tissue. In nude rats, SWs at the low-
energy energy flux density of 0.05 mJ/mm2 with an increasing
impulse rate that ranged from 500 to 2000 were applied to the
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adductor muscles of right hind limbs. The untreated left hind
limbs were used as negative controls, whereas induction of
acute hind limb ischemia in other animals served as positive
controls. In untreated hind limbs, mRNA expression of the
chemoattractant factor SDF-1 was below the detection limit
(Figure 1A and 1B). SW treatment significantly upregulated
SDF-1 mRNA expression in nonischemic hind limbs when
1000 impulses were applied. Importantly, the increased
level of SDF-1 mRNA expression in SW-treated hind limbs
was comparable to levels observed in hind limbs subjected to
severe acute ischemia by ligation of the superficial and
profound femoral artery. The increase in SDF-1 expression
induced by SW treatment was detected in and around von
Willebrand factor–positive vessels but also in surrounding
myocytes by immunostaining (data not shown). Moreover,
SW treatment significantly upregulated the number of
VEGF cells per myocyte detected on frozen sections from
hind limbs treated at impulse numbers 1000 impulses
(Figure 2A and 2B).
Effect of SW Treatment on Tissue Morphology
and Apoptosis
To exclude tissue damage as a potential side effect of SW
treatment, we analyzed the hind limb muscles by hematoxylin
& eosin staining (Figure 3A) as well as by membrane staining
with an antibody against laminin (Figure 3B), and determined
the number of apoptotic cells (Figure 3C) and inflammatory
cells (data not shown) 24 hours after application of an energy
flux density of 0.05 mJ/mm2 at impulse rates ranging from
500 to 2000. Neither the histologic morphology, the number
of apoptotic cells, nor the invasion of inflammatory cells was
affected by SW treatment, excluding a major tissue injury
induced by low-dose SW therapy.
Effect of SW-Mediated Preconditioning on
EPC Recruitment
To test the hypothesis that the SW-induced upregulation of
chemoattractants in the adductor muscles is functionally
relevant for enhancement of the recruitment of intravenously
injected circulating EPCs, we pretreated the nonischemic
muscles of the right hind limb with SWs (0.05 mJ/mm2 at an
impulse rate between 500 and 2000) followed by intravenous
infusion of 106 human CM-Dil–labeled EPCs after 24 hours.
Animals were euthanized 24 hours after administration of the
cells. Confocal analysis of the histologic sections revealed a
significantly increased number of red fluorescent EPCs in the
preconditioned adductor muscles (Figure 4A and 4B).
To further investigate enhanced EPC homing in a more
clinically relevant setting, we used a model of unilateral
chronic hind limb ischemia in nude rats. In this model, the
recovery of blood flow after induction of limb ischemia
reached a plateau after 3 weeks with a relative limb
perfusion of 70% (ratio ischemic/nonischemic limb). Thus,
we initiated our experiments to investigate the effects of
SW-facilitated cell therapy at least 3 weeks after induction
of hind limb ischemia. Twenty-four hours after precondi-
tioning of the chronic ischemic adductor muscles by SW
treatment, 106 human EPCs were intravenously injected.
After 14 days, we assessed changes in limb perfusion by
laser Doppler imaging. Neither EPC injections alone
(increase relative to the control group: 5.14.9%, P0.6)
nor SW treatment alone (9.37.7%, P0.3) significantly
enhanced perfusion of chronic ischemic limbs compared
with nontreated rats. In contrast, SW preconditioning 24
hours before EPC injection resulted in a significantly
enhanced blood flow recovery in the chronic ischemic hind
limb as compared with untreated limbs (Figure 5).
Discussion
The present study demonstrates that pretreatment of the target
tissue with low-energy SW therapy facilitates recruitment of
infused progenitor cells into nonischemic tissue and, most
important, into chronic ischemic tissue. Functionally, in a rat
model of chronic hind limb ischemia, which mimics the
clinical setting of patients with chronic ischemia, the com-
bined treatment with low-energy SWs followed by intrave-
Figure 1. Expression of SDF-1 mRNA after SW treatment. (A) Expression of SDF-1 mRNA is determined in nonischemic hind limb
adductor muscles after SW therapy with an energy density level of 0.05 mJ/mm2 and increasing numbers of impulses. GAPDH is used
as a loading control. Hind limb ischemia (HLI) served as a positive control. (B) Quantification is given as a ratio of SDF-1 expression
versus GAPDH for 3 animals (*P0.05 versus no impulses). SDF-1 expression was below detection levels at 0 and 500 impulses.
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nously administered EPCs translated into enhanced blood
flow recovery. These data demonstrate proof-of-principle for
the use of SW preconditioning for improving the efficacy of
cell therapy to enhance neovascularization, and thus could
have major implications for the emerging field of regenera-
tive medicine.
Low-energy SW therapy alone effectively induced an-
giogenesis and ameliorated chronic ischemia in animals
and humans without cell therapy,19,20 possibly by augment-
ing the expression of proangiogenic cytokines such as
VEGF. Mechanistically, we not only confirm these previ-
ous studies with respect to upregulation of VEGF19 but
also demonstrate that low-energy SWs significantly up-
regulate expression of the chemoattractant SDF-1 in
treated muscles. SDF-1 is a specific ligand for CXCR4,
which is strongly expressed on EPCs and hematopoietic
stem cells and plays a crucial role in cell homing and
function.26 –29 Specifically, EPCs derived from mice with a
heterozygous expression of CXCR4 (homozygous knock-
out mice are lethal) exhibit a significantly lower vascular
incorporation rate and fail to augment neovascularization
after ischemia.27 Moreover, overexpression of the CXCR4
ligand SDF-1 plays a key role for trapping and positioning
a subpopulation of circulating proangiogenic myeloid cells
around the growing vessels in tissues.12 In this model,
VEGF is critically involved in the recruitment of a
heterogeneous mix of myeloid cells from the bone marrow
to the blood as VEGF overexpression also induces expres-
sion of SDF-1 in mural cells around blood vessels. Then,
a subpopulation of bone marrow– derived cells that express
CXCR4 is recruited, captured, and positioned around the
vessels that express SDF-1. This proangiogenic subpopu-
lation stimulates endothelial cell sprouting by release of
matrix metalloproteinase-9 and other angiogenic factors.
Figure 2. A, Effect of SW treatment on the number of VEGF cells per myocyte. VEGF cells (green) and nuclear staining (blue) are
shown after SW therapy with an energy density level of 0.05 mJ/mm2 and increasing numbers of impulses (co: control, untreated hind
limb). B, Quantification for up to 9 sections per animal with at least 5 animals per group is shown (*P0.01 versus no impulses). HLI
indicates hind limb ischemia.
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In our experiments, histological analysis revealed that
homing of circulating EPC to untreated nonischemic tissue
was an extremely rare event. We already obtained a
significant increase in the number of retrieved EPCs in
tissues treated with 500 impulses; however, EPC recruit-
ment usually follows the enhanced expression of SDF-1,
which was observed at 1000 impulses, whereas a signifi-
cant increase in VEGF expression was only observed for
the application of 2000 impulses. Together with the fact
that EPCs strongly express the CXCR4 receptor,27 these
data suggest that the SW-induced SDF-1 expression might
be the predominant mechanism for the enhanced recruit-
ment of EPCs after SW treatment.
Intriguingly, in a rat model of chronic hind limb
ischemia, the neovascularization-enhancing effect of EPC
therapy, which was virtually lost in chronic ischemic
tissue, was rescued by pretreatment of the tissue with
low-energy SW therapy. Systemic infusion of EPCs alone
did not result in a significant improvement in the recovery
of the blood flow in the chronic ischemic limb. The lack of
efficacy of EPC infusion alone is not much of a surprise as,
in this model at the time of EPC treatment, the enhanced
expression of chemoattractants after induction of ischemia
has already returned to baseline levels.17 This can be well
rationalized by the observation that EPC mobilization
peaks on day 7 after onset of acute myocardial infarction
and returns to baseline levels thereafter.30 Therefore, in our
setting of chronic limb ischemia, EPC recruitment after
systemic infusion was most likely insufficient to result in
a detectable enhancement of limb perfusion recovery.
Because most patients suitable for cell therapy do not
suffer from acute tissue ischemia but rather endure chronic
tissue ischemia, our study design certainly bears great
clinical relevance. Indeed, recent studies demonstrate that
the cardiac improvement induced by infused EPC in patients
with chronic myocardial infarction is markedly reduced as
compared with patients with acute myocardial infarction.1,5,31 In
the present study, we were able to demonstrate consistently that
the combination of low-energy SW treatment and cell therapy in
chronic ischemic tissue resulted in a significant stimulation of
blood flow recovery in chronic ischemic limbs, whereas EPC
treatment alone did not.
Figure 3. Effect of SW treatment on tissue morphology and survival. (A) Hematoxylin & eosin staining and (B) membrane staining by
laminin do not reveal any SW-related tissue damage after SW therapy with energy flux density levels of 0.05 mJ/mm2 and an increasing
number of impulses. Hind limb ischemia (HLI) served as a positive control. (C) In addition, the apoptotic rate was not affected by SW
treatment. In vitro treatment with DNAse was used as positive control.
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Previous work by Hiasa et al32 has already taken
advantage of the cell recruitment– enhancing properties of
SDF-1 by transfecting plasmid DNA encoding for SDF-1
into ischemic muscles. Their studies demonstrated that
SDF-1 gene transfer augments ischemia-induced vasculo-
genesis and angiogenesis in vivo. The delivery of vectors
to allow for targeted expression of growth factors or
cytokines has been challenging, particularly in the clinical
setting. In contrast, SW therapy is a noninvasive technique,
widely used for clinical treatment without major compli-
cations, and does not require introduction of genetic
material.33 High-energy extracorporeal SW therapy, as
opposed to the low-energy modus used for the present
study, has been commonly used to fragmentize kidney
stones for 20 years.18 SWs are amplitudes of acoustic
pulse waves similar to ultrasound with extremely high
positive pressures (up to 100 MPa) and negative pressure
of about 10 MPa. Cavitation bubbles are formed in the
trailing, negative pressure cycle after the SW front. When
the cavitation bubble collapses, a transient SW emission
and jet formation is generated.34 Beside cavitation, shear
forces are generated through the transient pressure pulse.
Whereas cavitation is known to increase permeability of
the cell membrane, shear forces could result in induction of
gene expression. However, this issue is still a matter of
debate and certainly deserves further investigation. With
respect to low-energy SWs, which share the physical
features of high-energy SWs, initial clinical pilot data
indicate that repetitive extracorporeal cardiac SW therapy
in patients with severe coronary artery disease is safe and
feasible.20 In the present study, low-energy SWs consis-
tently did not induce tissue damage or apoptosis, which
provides further evidence that low-energy SW treatment is
generally well tolerated. Therefore, one may speculate that
preexposure of hearts or limbs to low-energy SWs prior to
intravascular cell therapy may be well suited to augment
stem and progenitor cell recruitment to chronic or even
nonischemic tissue (eg, dilative cardiomyopathy), and to
subsequently enhance functional recovery in these
patients.
Acknowledgments
We thank Marion Muhly-Reinholz, Ariane Fischer, and Tino Röxe
for their excellent technical assistance. We are grateful to Dr
Figure 4. Recruitment of circulating EPCs to nonischemic tissue is augmented after SW preconditioning. A, Effect of SW pretreatment
with energy flux density levels of 0.05 mJ/mm2 and 500 to 2000 impulses, (co: control, untreated hind limb). SWs were applied 24
hours prior to intravenous injection of human EPCs. Then, numbers of recruited EPCs in the adductor muscles were determined.
*P0.05 versus no impulses (up to 11 sections per animal checked for mice in control [n7], 500 [n7], 1000 [n8], 2000 [n7], and
hind limb ischemia [HLI] [n3] groups, respectively). B, Recruited CM-Dil EPCs exhibit red fluorescence, von Willebrand factor is used
as endothelial marker (green), membrane staining is performed by laminin (white), and nuclei (Sytox blue) are blue.
Figure 5. Effect of SW preconditioning on perfusion in unilateral
chronic ischemic tissue. Effect of SW pretreatment 24 hours
prior to intravenous injection of human EPCs assessed by laser
Doppler imaging. The increase in perfusion is calculated com-
pared with chronically ischemic rats without treatment (control,
7 rats; EPC, 10 rats; SW, 7 rats; combined, 9 rats). *P0.01
versus untreated; **P0.053 versus EPC treatment.
6 Circulation December 19/26, 2006
 by on June 24, 2010 circ.ahajournals.orgDownloaded from 
Andreas Lutz (Dornier MedTech Systems GmbH) for helpful
discussions.
Sources of Funding
This work was supported by the Deutsche Forschungsgemeinschaft
(FOR 501: He3044/2-2, Wa1461/2-2, and TR23), the Alfried Krupp-
Stiftung, and the Leducq Foundation.
Disclosures
Drs Aicher, Heeschen, Dimmeler, and Zeiher are named as co-
inventors on a patent application (Shock wave pretreatment as a
therapeutic tool for targeted recruitment of stem/progenitor cells)
filed by Dornier MedTech Systems GmbH.
References
1. Assmus B, Schachinger V, Teupe C, Britten M, Lehmann R, Dobert N,
Grunwald F, Aicher A, Urbich C, Martin H, Hoelzer D, Dimmeler S,
Zeiher AM. Transplantation of Progenitor Cells and Regeneration
Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circu-
lation. 2002;106:3009–3017.
2. Strauer BE, Brehm M, Zeus T, Kostering M, Hernandez A, Sorg RV,
Kogler G, Wernet P. Repair of infarcted myocardium by autologous
intracoronary mononuclear bone marrow cell transplantation in
humans. Circulation. 2002;106:1913–1918.
3. Wollert KC, Meyer GP, Lotz J, Ringes-Lichtenberg S, Lippolt P,
Breidenbach C, Fichtner S, Korte T, Hornig B, Messinger D, Arseniev
L, Hertenstein B, Ganser A, Drexler H. Intracoronary autologous
bone-marrow cell transfer after myocardial infarction: the BOOST
randomised controlled clinical trial. Lancet. 2004;364:141–148.
4. Strauer BE, Brehm M, Zeus T, Bartsch T, Schannwell C, Antke C,
Sorg RV, Kogler G, Wernet P, Muller HW, Kostering M. Regen-
eration of human infarcted heart muscle by intracoronary autologous
bone marrow cell transplantation in chronic coronary artery disease:
the IACT Study. J Am Coll Cardiol. 2005;46:1651–1658.
5. Assmus B HJ, Schächinger V, Britten MB, Fischer-Rasokat U,
Lehmann R, Teupe C, Pistorius K, Martin M, Abolmaali N, Tonn T,
Dimmeler S, Zeiher AM. Transcoronary transplantation of progenitor
cells after myocardial infarction. N Engl J Med. 2006;355:1222–1232.
6. Janssens S, Dubois C, Bogaert J, Theunissen K, Deroose C, Desmet
W, Kalantzi M, Herbots L, Sinnaeve P, Dens J, Maertens J, Rade-
makers F, Dymarkowski S, Gheysens O, Van Cleemput J, Bormans G,
Nuyts J, Belmans A, Mortelmans L, Boogaerts M, Van de Werf F.
Autologous bone marrow-derived stem-cell transfer in patients with
ST-segment elevation myocardial infarction: double-blind, ran-
domised controlled trial. Lancet. 2006;367:113–121.
7. Tse HF, Kwong YL, Chan JK, Lo G, Ho CL, Lau CP. Angiogenesis
in ischaemic myocardium by intramyocardial autologous bone marrow
mononuclear cell implantation. Lancet. 2003;361:47– 49.
8. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T,
Witzenbichler B, Schatteman G, Isner JM. Isolation of putative pro-
genitor endothelial cells for angiogenesis. Science. 1997;275:
964 –967.
9. Lee SH, Wolf PL, Escudero R, Deutsch R, Jamieson SW, This-
tlethwaite PA. Early expression of angiogenesis factors in acute myo-
cardial ischemia and infarction. N Engl J Med. 2000;342:626 – 633.
10. Yamaguchi J, Kusano KF, Masuo O, Kawamoto A, Silver M,
Murasawa S, Bosch-Marce M, Masuda H, Losordo DW, Isner JM,
Asahara T. Stromal cell-derived factor-1 effects on ex vivo expanded
endothelial progenitor cell recruitment for ischemic neovascular-
ization. Circulation. 2003;107:1322–1328.
11. De Falco E, Porcelli D, Torella AR, Straino S, Iachininoto MG,
Orlandi A, Truffa S, Biglioli P, Napolitano M, Capogrossi MC, Pesce
M. SDF-1 involvement in endothelial phenotype and ischemia-
induced recruitment of bone marrow progenitor cells. Blood. 2004;
104:3472–3482.
12. Grunewald M, Avraham I, Dor Y, Bachar-Lustig E, Itin A, Yung S,
Chimenti S, Landsman L, Abramovitch R, Keshet E. VEGF-induced
adult neovascularization: recruitment, retention, and role of accessory
cells. Cell. 2006;124:175–189.
13. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, Inai
Y, Silver M, Isner JM. VEGF contributes to postnatal neovascular-
ization by mobilizing bone marrow-derived endothelial progenitor
cells. EMBO J. 1999;18:3964 –3972.
14. Ruck A, Gustafsson T, Norrbom J, Nowak J, Kallner G, Soderberg M,
Sylven C, Drvota V. ANP and BNP but not VEGF are regionally
overexpressed in ischemic human myocardium. Biochem Biophys Res
Commun. 2004;322:287–291.
15. Damas JK, Eiken HG, Oie E, Bjerkeli V, Yndestad A, Ueland T,
Tonnessen T, Geiran OR, Aass H, Simonsen S, Christensen G,
Froland SS, Attramadal H, Gullestad L, Aukrust P. Myocardial
expression of CC- and CXC-chemokines and their receptors in human
end-stage heart failure. Cardiovasc Res. 2000;47:778 –787.
16. Damas JK, Waehre T, Yndestad A, Ueland T, Muller F, Eiken HG,
Holm AM, Halvorsen B, Froland SS, Gullestad L, Aukrust P. Stromal
cell-derived factor-1alpha in unstable angina: potential antiinflam-
matory and matrix-stabilizing effects. Circulation. 2002;106:36 – 42.
17. Ma J, Ge J, Zhang S, Sun A, Shen J, Chen L, Wang K, Zou Y. Time
course of myocardial stromal cell-derived factor 1 expression and
beneficial effects of intravenously administered bone marrow stem
cells in rats with experimental myocardial infarction. Basic Res
Cardiol. 2005;100:217–223.
18. Chaussy C, Schmiedt E, Jocham D, Brendel W, Forssmann B, Walther
V. First clinical experience with extracorporeally induced destruction
of kidney stones by shock waves. J Urol. 1982;127:417– 420.
19. Nishida T, Shimokawa H, Oi K, Tatewaki H, Uwatoku T, Abe K,
Matsumoto Y, Kajihara N, Eto M, Matsuda T, Yasui H, Takeshita A,
Sunagawa K. Extracorporeal cardiac shock wave therapy markedly
ameliorates ischemia-induced myocardial dysfunction in pigs in vivo.
Circulation. 2004;110:3055–3061.
20. Fukumoto Y, Ito A, Uwatoku T, Matoba T, Kishi T, Tanaka H,
Takeshita A, Sunagawa K, Shimokawa H. Extracorporeal cardiac
shock wave therapy ameliorates myocardial ischemia in patients with
severe coronary artery disease. Coron Artery Dis. 2006;17:63–70.
21. Gotte G, Amelio E, Russo S, Marlinghaus E, Musci G, Suzuki H.
Short-time non-enzymatic nitric oxide synthesis from L-arginine and
hydrogen peroxide induced by shock waves treatment. FEBS Lett.
2002;520:153–155.
22. Wang CJ, Wang FS, Yang KD, Weng LH, Hsu CC, Huang CS, Yang
LC. Shock wave therapy induces neovascularization at the
tendon-bone junction. A study in rabbits. J Orthop Res. 2003;21:
984 –989.
23. Park JK, Cui Y, Kim MK, Kim YG, Kim SH, Kim SZ, Cho KW.
Effects of extracorporeal shock wave lithotripsy on plasma levels of
nitric oxide and cyclic nucleotides in human subjects. J Urol. 2002;
168:38 – 42.
24. Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann
M, Rutten H, Fichtlscherer S, Martin H, Zeiher AM. HMG-CoA
reductase inhibitors (statins) increase endothelial progenitor cells via
the PI 3-kinase/Akt pathway. J Clin Invest. 2001;108:391–397.
25. Urbich C, Heeschen C, Aicher A, Dernbach E, Zeiher AM, Dimmeler
S. Relevance of monocytic features for neovascularization capacity of
circulating endothelial progenitor cells. Circulation. 2003;108:
2511–2516.
26. Jo DY, Rafii S, Hamada T, Moore MA. Chemotaxis of primitive
hematopoietic cells in response to stromal cell-derived factor-1. J Clin
Invest. 2000;105:101–111.
27. Walter DH, Haendeler J, Reinhold J, Rochwalsky U, Seeger F, Honold
J, Hoffmann J, Urbich C, Lehmann R, Arenzana-Seisdesdos F, Aicher
A, Heeschen C, Fichtlscherer S, Zeiher AM, Dimmeler S. Impaired
CXCR4 signaling contributes to the reduced neovascularization
capacity of endothelial progenitor cells from patients with coronary
artery disease. Circ Res. 2005;97:1142–1151.
28. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N,
Kleinman ME, Capla JM, Galiano RD, Levine JP, Gurtner GC. Pro-
genitor cell trafficking is regulated by hypoxic gradients through
HIF-1 induction of SDF-1. Nat Med. 2004;10:858 – 864.
29. Askari AT, Unzek S, Popovic ZB, Goldman CK, Forudi F, Kiedrowski
M, Rovner A, Ellis SG, Thomas JD, DiCorleto PE, Topol EJ, Penn
MS. Effect of stromal-cell-derived factor 1 on stem-cell homing and
tissue regeneration in ischaemic cardiomyopathy. Lancet. 2003;362:
697–703.
30. Shintani S, Murohara T, Ikeda H, Ueno T, Honma T, Katoh A, Sasaki
K, Shimada T, Oike Y, Imaizumi T. Mobilization of endothelial
progenitor cells in patients with acute myocardial infarction. Circu-
lation. 2001;103:2776 –2779.
Aicher et al Shock Wave for Cell Therapy Enhancement 7
 by on June 24, 2010 circ.ahajournals.orgDownloaded from 
31. Schachinger V, Assmus B, Britten MB, Honold J, Lehmann R, Teupe
C, Abolmaali ND, Vogl TJ, Hofmann WK, Martin H, Dimmeler S,
Zeiher AM. Transplantation of progenitor cells and regeneration
enhancement in acute myocardial infarction: final one-year results of
the TOPCARE-AMI Trial. J Am Coll Cardiol. 2004;44:1690 –1699.
32. Hiasa K, Ishibashi M, Ohtani K, Inoue S, Zhao Q, Kitamoto S, Sata
M, Ichiki T, Takeshita A, Egashira K. Gene transfer of stromal
cell-derived factor-1alpha enhances ischemic vasculogenesis and
angiogenesis via vascular endothelial growth factor/endothelial nitric
oxide synthase-related pathway: next-generation chemokine therapy
for therapeutic neovascularization. Circulation. 2004;109:2454 –2461.
33. Skolarikos A, Alivizatos G, de la Rosette J. Extracorporeal shock
wave lithotripsy 25 years later: complications and their prevention.
Eur Urol. 2006;50:981–990.
34. Ogden JA, Toth-Kischkat A, Schultheiss R. Principles of shock wave
therapy. Clin Orthop Relat Res. 2001:8 –17.
CLINICAL PERSPECTIVE
Stem and progenitor cell therapy is a novel approach to improve neovascularization and function of ischemic tissue.
Enhanced tissue expression of chemoattractant factors such as stromal cell–derived factor 1 and vascular endothelial
growth factor is crucial for the recruitment of circulating endothelial progenitor cells (EPCs) during acute ischemia. In
chronic ischemia, however, expression of these chemoattractants is less pronounced, which results in insufficient EPC
recruitment into the target tissue. Therefore, we investigated the effect of targeted extracorporeal shock wave application
to facilitate EPC recruitment into nonischemic and chronic ischemic tissue. Preconditioning of both nonischemic and
chronic ischemic tissue with low-energy shock waves improves recruitment of circulating EPCs via enhanced expression
of chemoattractant factors such as vascular endothelial growth factor or stromal cell–derived factor 1. Functionally, in a
rat model of chronic hind limb ischemia, which mimics the clinical setting of patients with chronic ischemia, the combined
treatment with low-energy shock waves followed by intravenously administered EPCs translated into enhanced blood flow
recovery. These data demonstrate proof-of-principle for the use of shock wave preconditioning to improve the efficacy of
cell therapy to induce neovascularization, and, thus, could have major implications for the emerging field of regenerative
medicine.
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